Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nanoscope Therapeutics announced on January 5, 2026 that CEO Sulagna Bhattacharya will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2026, highlighting the company’s regulatory achievements and clinical progress in optogenetic therapies for retinal diseases. The presentation will spotlight key advances, including the rolling Biologics License Application (BLA) for retinitis pigmentosa and durable vision improvements observed in the REMAIN study of MCO-010, as well as anticipated milestones in Stargardt disease and geographic atrophy in 2026. This appearance underscores Nanoscope’s momentum in developing its disease-agnostic Multi-Characteristic Opsin (MCO) platform aimed at restoring vision for patients with photoreceptor degeneration. 
Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference